Contributor since: 2012
Latest Articles
Billionaires Club Investing In ChromaDex As Revenue Grows
Allergan Was Correct To Fight The Legal Theft Of Property
Innovation Pharmaceuticals Stock May Be A Triple-Crown Winner With Brilacidin By Year End
ChromaDex: Response To The Claim Niagen Is Just 'Expensive Vitamin B3'
Dornase Alfa (Genentech's Pulmozyme) Used Successfully Off-Label For Alzheimer's
Niagen Continues To Drive Revenue Of ChromaDex Stock
Interview With New Cellceutix President Dr A Bertolino
Potential Niagen Health Benefits Drive Revenue Of ChromaDex Stock
Cellceutix Completes Successful Prurisol Phase 2 For Psoriasis
An Interview With Cellceutix CEO Leo Ehrlich
Cellceutix Undervalued By 90+%; Expect A Short Squeeze Soon
Many Sharp Minds Are Invested Long In Tekmira
Ebola Treated With GlaxoSmithKline Subsidiary HIV Product
Regulatory Support Creates Opportunity For Antibiotic Makers Otonomy And Cellceutix
Update: Tekmira Pharmaceuticals Corp. Has A Framework To Treat Ebola Patients
Update: Cellceutix Calls Out To President Obama About Brilacidin
Update: Cellceutix's Antibiotic Brilacidin Should Move Share Price Before Kevetrin Or Prurisol
4 Companies To Look At After WHO Ebola Consultation In Geneva
Tekmira Pharmaceuticals Is More Than Just A Short-Term Ebola Trade
Interview With Leo Ehrlich, Cellceutix CEO Following Acquisition Of PolyMedix Assets
Holloman Energy Corp.: Drilling To Start In Australia's Cooper Basin Any Day Now
International Stem Cell Solves Immune Rejection Issue For Significant Segment Of Population
An Interview With Leo Ehrlich, Cellceutix CEO
Which Drug Moves Cellceutix First: Kevetrin Or Prurisol?
Why The Aspire Deal Is A Winner For Cellceutix Shareholders
Watch Cellceutix Closely For Potential Catalysts In 2013